BANGKOK, July 13 (TNA) – A COVID-19 vaccine prototype
being developed by Thai researchers will enter human trials as early as October
this year.
The mRNA vaccine prototype has been developed by Thai
researchers at Chulalongkorn University’s Centre of Excellence in Vaccine
Research and Development.
Professor Dr. Kiat Ruxrungtham, head of the research team, said phase
two of vaccine trial in monkeys, which began last month, had showed great
results.
The team planned to start a clinical trial in humans between
October and December. From September, applications for vaccine trial volunteers
would be accepted, he said.
Seventy five volunteers in the first phase of human trial
would be divided into two age groups; 18-60 and 60-80. If the results turned out as planned, a
second phase would begin around the end of this year, expanding to 500-1,000
volunteers, said Dr. Kiat.
A local biotechnology company has been tasked with mass
production of coronavirus vaccines to ensure sufficient vaccines for Thai
people. (TNA)
